High triglyceride causes: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Tags: Manual revert Visual edit
 
(33 intermediate revisions by 10 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Triglyceride}}
{{Hyperlipoproteinemia}}
{{CMG}}; {{AE}} [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com]; {{Ochuko}}


{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com]
==Overview==
[[Hypertriglyceridemia]] can occur due to various causes, including genetics, familial, metabolic and drugs.


==Overview==
[[Hypertriglyceridemia]] can occur due to various causes, including genetics, familial, metabolic and drugs
==Causes==
==Causes==
===Life Threatening Causes===
===Life Threatening Causes===
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Hypertriglyceridemia does not have life threatening causes.


===Common Causes===
===Common Causes===
Line 18: Line 20:
{|style="width:80%; height:100px" border="1"
{|style="width:80%; height:100px" border="1"
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | [[Alström syndrome]], [[apolipoprotein E|apoprotein E deficiency]], [[high chylomicron|chylomicron levels raised (plasma)]], [[familial chylomicronemia]], [[familial combined hyperlipidemia]], [[familial hypertriglyceridemia]], [[hyperlipoproteinemia type V|hyperlipoproteinemia, familial type 5]], [[IDL|intermediate density lipoprotein levels raised (plasma or serum)]]
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | [[Alström syndrome]], [[apolipoprotein E|apoprotein E deficiency]], [[high chylomicron|chylomicron levels raised (plasma)]], [[familial chylomicronemia]], [[familial combined hyperlipidemia]], [[familial hypertriglyceridemia]], [[hyperlipoproteinemia type V|hyperlipoproteinemia, familial type 5]], [[IDL|intermediate density lipoprotein levels raised (plasma or serum)]], [[metabolic syndrome]], [[reaven syndrome|Reaven syndrome X]]
|-
|-
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
Line 29: Line 31:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Dermatologic'''
| '''Dermatologic'''
|bgcolor="Beige"| [[Systemic lupus erythematosus]]
|bgcolor="Beige"| [[Systemic lupus erythematosus]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Drug Side Effect'''
| '''Drug Side Effect'''
|bgcolor="Beige"| [[Amprenavir]], [[atazanavir|atazanavir sulfate]], [[atypical  antipsychotics]], [[bendrofluazide]], [[beta-blockers]], [[bexarotene]], [[chlorthalidone]], [[clomiphene]], [[colesevelam|colesevelam hydrochloride]], [[colestyramine]], [[combined oral contraceptive pill]], [[desvenlafaxine]], [[diuretics]], [[estrogen replacement  therapy]], [[fosamprenavir]], [[glucocorticoids]], [[hydrochlorothiazide]], [[interferon alpha]], [[linagliptin]], [[lopinavir]], [[mirtazapine]], [[non-nucleoside reverse  transcriptase inhibitors]], [[olanzapine]], [[isotretinoin|oral isotretinoin]], [[propofol]], [[protease inhibitors]], [[ritonavir]], [[saquinavir]], [[tamoxifen]], [[temsirolimus]], [[tipranavir]], [[tocilizumab]]
|bgcolor="Beige"| [[Abiraterone]], [[Amprenavir]], [[atazanavir|atazanavir sulfate]], [[atypical  antipsychotics]], [[bendrofluazide]], [[beta-blockers]], [[bexarotene]], [[chlorthalidone]], [[clomiphene]], [[colesevelam|colesevelam hydrochloride]], [[colestyramine]], [[combined oral contraceptive pill]], [[desvenlafaxine]], [[diuretics]], [[Drospirenone and Ethinyl estradiol]], [[Efavirenz]], [[estrogen replacement  therapy]], [[febuxostat]], [[fosamprenavir]], [[glucocorticoids]], [[hydrochlorothiazide]], [[interferon alpha]], [[Interferon alfa-2b ]], [[Indinavir]], [[Interferon gamma]],  [[linagliptin]], [[lopinavir]], [[Medroxyprogesterone]],  [[mirtazapine]], [[non-nucleoside reverse  transcriptase inhibitors]], [[Norethindrone acetate and Ethinyl estradiol]], [[Norgestimate and Ethinyl estradiol]], [[Norgestrel and Ethinyl estradiol]], [[olanzapine]], [[isotretinoin|oral isotretinoin]], [[Pegaspargase]], [[Pegylated interferon alfa-2b]], [[propofol]], [[protease inhibitors]], [[raloxifene]], [[ritonavir]], [[Ruxolitinib]],[[saquinavir]], [[Siltuximab]], [[tamoxifen]], [[tazarotene]], [[temsirolimus]], [[tipranavir]], [[tocilizumab]], [[Tretinoin]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 53: Line 55:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Genetic'''
| '''Genetic'''
|bgcolor="Beige"| [[Alagille  syndrome]], [[Alström syndrome]], [[apolipoprotein E|apoprotein E deficiency]], [[carnitine palmitoyltransferase 1 deficiency]], [[cholesteryl ester storage disease]], [[congenital generalized lipodystrophy|congenital generalized lipodystrophy type 1]], [[apolipoprotein C2|deficiency of apolipoprotein C2 ]], [[familial chylomicronemia]], [[familial combined  hyperlipidemia]], [[familial histiocytic  reticulosis]], [[familial hypertriglyceridemia]], [[fish eye disease]], [[glycogen storage disease|Glycogen storage disease type 1]], [[glycogenosis type 1a]], [[hyperlipoproteinemia type V|hyperlipoproteinemia, familial type 5]], [[lecithin cholesterol acyltransferase deficiency]], [[metabolic syndrome]], [[Niemann-Pick disease|Niemann-Pick disease type B]], [[reaven syndrome|Reaven syndrome X]], [[sphingomyelinase  deficiency]], [[Tangier disease]]
|bgcolor="Beige"| [[Alagille  syndrome]], [[Alström syndrome]], [[apolipoprotein E|apoprotein E deficiency]], [[carnitine palmitoyltransferase 1 deficiency]], [[cholesteryl ester storage disease]], [[congenital generalized lipodystrophy|congenital generalized lipodystrophy type 1]], [[apolipoprotein C2|deficiency of apolipoprotein C2 ]], [[familial chylomicronemia]], [[familial combined  hyperlipidemia]], [[familial histiocytic  reticulosis]], [[familial hypertriglyceridemia]], [[fish eye disease]], [[glycogen storage disease|glycogen storage disease type 1]], [[glycogenosis type 1a]], [[hyperlipoproteinemia type V|hyperlipoproteinemia, familial type 5]], [[lecithin cholesterol acyltransferase deficiency]], [[metabolic syndrome]], [[Niemann-Pick disease|Niemann-Pick disease type B]], [[reaven syndrome|Reaven syndrome X]], [[sphingomyelinase  deficiency]], [[Tangier disease]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Hematologic'''
| '''Hematologic'''
|bgcolor="Beige"| [[Familial histiocytic reticulosis]]
|bgcolor="Beige"| [[Familial histiocytic reticulosis]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Iatrogenic'''
| '''Iatrogenic'''
|bgcolor="Beige"| [[Parenteral nutrition]]
|bgcolor="Beige"| [[Parenteral nutrition]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 73: Line 75:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Neurologic'''
| '''Neurologic'''
|bgcolor="Beige"| [[Niemann-Pick disease|Niemann-Pick disease type B]], [[sphingomyelinase deficiency]]
|bgcolor="Beige"| [[Niemann-Pick disease|Niemann-Pick disease type B]], [[sphingomyelinase deficiency]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Nutritional/Metabolic'''
| '''Nutritional/Metabolic'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Alcohol]], [[apolipoprotein E|apoprotein E deficiency]], [[high chylomicron|chylomicron levels raised (plasma)]], [[apolipoprotein C2|deficiency of apolipoprotein C2]], [[familial chylomicronemia]], [[familial combined hyperlipidemia]], [[familial hypertriglyceridemia]], [[glycogen storage disease|glycogen storage disease type 1]], [[glycogenosis type 1a]], [[carbohydrate|high carbohydrate or high  glycemic index]], [[hyperlipoproteinemia type V|hyperlipoproteinemia, familial type 5]], [[IDL|intermediate density  lipoprotein levels raised (plasma or serum)]], [[lipodystrophy]], [[lipoprotein lipase  deficiency]], [[metabolic syndrome]], [[obesity]], [[reaven syndrome|Reaven syndrome X]], [[Tangier disease]], [[VLDL|very low density lipoprotein levels raised (plasma or serum)]], [[vitamin E deficiency|vitamin E deficiency, familial isolated]]
 
[[Alcohol]],  
 
[[Apoprotein E deficiency]],  
 
[[Chylomicron levels raised (plasma)]],  
 
[[Deficiency of apolipoprotein C2 ]],  
 
[[Familial  chylomicronemia]],  
 
[[Familial combined hyperlipidemia]],  
 
[[Familial  hypertriglyceridemia]],  
 
[[Glycogen storage disease type 1]],  
 
[[Glycogenosis type 1a]],  
 
[[High carbohydrate or high  glycemic index]],  
 
[[Hyperlipoproteinemia, familial type 5]],  
 
[[Intermediate density  lipoprotein levels raised (plasma or serum)]],  
 
[[Lipodystrophy]],  
 
[[Lipoprotein lipase  deficiency]],  
 
[[Obesity]],  
 
[[Tangier disease]],  
 
[[Very low density lipoprotein levels raised (plasma or serum)]],  
 
[[Vitamin E deficiency, familial isolated]],
 
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Obstetric/Gynecologic'''
| '''Obstetric/Gynecologic'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Polycystic ovary syndrome]], [[pregnancy]]
[[Polycystic ovary syndrome]],  
 
[[Pregnancy]],
 
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 130: Line 91:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Ophthalmologic'''
| '''Ophthalmologic'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Diabetes mellitus]], [[Lecithin cholesterol acyltransferase deficiency]]
[[Diabetes mellitus]],  
 
[[Lecithin cholesterol acyltransferase deficiency]],
 
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Overdose/Toxicity'''
| '''Overdose/Toxicity'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Alcohol]]
[[Alcohol]],
 
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 152: Line 107:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Renal/Electrolyte'''
| '''Renal/Electrolyte'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Chronic kidney disease]], [[chronic renal insufficiency]], [[diabetes mellitus]], [[nephrotic syndrome]], [[systemic lupus erythematosus]]
[[Chronic kidney disease]],  
 
[[Chronic renal insufficiency]],  
 
[[Diabetes mellitus]],  
 
[[Nephrotic syndrome]],  
 
[[Systemic lupus erythematosus]],
 
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Rheumatology/Immunology/Allergy'''
| '''Rheumatology/Immunology/Allergy'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Macrophage activation syndrome]], [[metabolic syndrome]], [[paraproteinemias]], [[reaven syndrome|Reaven syndrome X]], [[systemic lupus erythematosus]]
[[Macrophage activation syndrome]],  
 
[[Metabolic syndrome]],  
 
[[Paraproteinemias]],  
 
[[Reaven syndrome X]],  
 
[[Systemic lupus erythematosus]],
 
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 192: Line 127:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Miscellaneous'''
| '''Miscellaneous'''
|bgcolor="Beige"|  
|bgcolor="Beige"| [[Alcohol]]
[[Alcohol]],
 
|-
|-
|}
|}


===Causes in Alphabetical Order===
===Causes in Alphabetical Order===
{{MultiCol}}
{{col-begin|width=80%}}
{{col-break|width=33%}}
*[[Acute  pancreatitis]]
*[[Acute  pancreatitis]]
*[[Alagille syndrome]]
*[[Alagille syndrome]]
Line 226: Line 160:
*[[Desvenlafaxine]]
*[[Desvenlafaxine]]
*[[Diabetes mellitus]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Diabetes mellitus]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
{{col-break|width=33%}}
*[[Diuretics]]
*[[Diuretics]]
*[[Efavirenz]]
*[[Estrogen replacement  therapy]]
*[[Estrogen replacement  therapy]]
*[[Familial chylomicronemia]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Familial chylomicronemia]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
Line 239: Line 175:
*[[carbohydrate|High carbohydrate or high  glycemic index]]  
*[[carbohydrate|High carbohydrate or high  glycemic index]]  
*[[Hydrochlorothiazide]]
*[[Hydrochlorothiazide]]
{{ColBreak}}
*[[hyperlipoproteinemia type V|Hyperlipoproteinemia,  familial type 5]]<ref name="pmid1078394">{{cite journal| author=Fallat RW, Glueck CJ| title=Familial and acquired type V hyperlipoproteinemia. | journal=Atherosclerosis | year= 1976 | volume= 23 | issue= 1 | pages= 41-62 | pmid=1078394 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1078394  }} </ref>
*[[hyperlipoproteinemia type V|Hyperlipoproteinemia,  familial type 5]]<ref name="pmid1078394">{{cite journal| author=Fallat RW, Glueck CJ| title=Familial and acquired type V hyperlipoproteinemia. | journal=Atherosclerosis | year= 1976 | volume= 23 | issue= 1 | pages= 41-62 | pmid=1078394 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1078394  }} </ref>
*[[Hypothyroidism]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Hypothyroidism]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Indinavir]]
*[[Insulin resistance]]   
*[[Insulin resistance]]   
*[[Interferon alpha]]
*[[Interferon alpha]]
*[[Interferon gamma]]
*[[IDL|Intermediate density  lipoprotein levels raised (plasma or serum)]]
*[[IDL|Intermediate density  lipoprotein levels raised (plasma or serum)]]
*[[Lecithin cholesterol  acyltransferase deficiency]]
*[[Lecithin cholesterol  acyltransferase deficiency]]
Line 252: Line 189:
*[[Lopinavir]]
*[[Lopinavir]]
*[[Macrophage activation  syndrome]]
*[[Macrophage activation  syndrome]]
*[[Medroxyprogesterone]]
*[[Metabolic syndrome]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Metabolic syndrome]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
{{col-break|width=33%}}
*[[Mirtazapine]]
*[[Mirtazapine]]
*[[Nephrotic syndrome]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Nephrotic syndrome]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
Line 258: Line 197:
*[[Non-alcoholic fatty liver disease]]  
*[[Non-alcoholic fatty liver disease]]  
*[[Non-nucleoside reverse transcriptase inhibitors]]
*[[Non-nucleoside reverse transcriptase inhibitors]]
*[[Norgestrel and Ethinyl estradiol]]
*[[Obesity]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Obesity]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858  }} </ref>
*[[Olanzapine]]
*[[Olanzapine]]
Line 263: Line 203:
*[[Paraproteinemias]]
*[[Paraproteinemias]]
*[[Parenteral nutrition]]   
*[[Parenteral nutrition]]   
*[[Pegaspargase]]
*[[Polycystic ovary syndrome]]   
*[[Polycystic ovary syndrome]]   
*[[Pregnancy]]
*[[Pregnancy]]
Line 270: Line 211:
*[[Ritonavir]]
*[[Ritonavir]]
*[[Saquinavir]]
*[[Saquinavir]]
*[[Siltuximab]]
*[[Sphingomyelinase deficiency]]  
*[[Sphingomyelinase deficiency]]  
*[[Systemic lupus erythematosus]]  
*[[Systemic lupus erythematosus]]  
Line 277: Line 219:
*[[Tipranavir]]
*[[Tipranavir]]
*[[Tocilizumab]]
*[[Tocilizumab]]
*[[Tretinoin]]
*[[VLDL|Very low density lipoprotein levels raised (plasma or serum)]]  
*[[VLDL|Very low density lipoprotein levels raised (plasma or serum)]]  
*[[vitamin E deficiency|Vitamin E deficiency, familial isolated]]
*[[vitamin E deficiency|Vitamin E deficiency, familial isolated]]
{{EndMultiCol}}
{{col-end}}
Diagnosis
 
== 2018 AHA ACC Guideline on the Management of Blood Cholesterol. Hypertriglyceridemia Recommendations ==
{| class="wikitable" style="width:80%"
|-
| colspan="1" style="text-align:center; background:LightGreen" | [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen" |<nowiki>"</nowiki>'''1.''' In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting triglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors (obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or nephrotic syndrome, hypothyroidism), and medications that increase triglycerides''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki>
|}
<ref name="pmid304233912">{{cite journal| author=Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS | display-authors=etal| title=2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=J Am Coll Cardiol | year= 2019 | volume= 73 | issue= 24 | pages= 3168-3209 | pmid=30423391 | doi=10.1016/j.jacc.2018.11.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30423391  }}</ref>
{| class="wikitable" style="width:80%"
|-
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon" |" 2'''.'''  In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or higher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to consider a persistently elevated triglyceride level as a factor favoring initiation or intensification of statin therapy (Level of Evidence B-R)".
|-
| bgcolor="LemonChiffon" |<nowiki>''</nowiki> 3. In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high triglyceride and to initiate statin therapy (Level of Evidence B-R)<nowiki>''</nowiki>
|-
| bgcolor="LemonChiffon" |<nowiki>''</nowiki>4.  In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and especially fasting triglycerides ≥1000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other causes of hypertriglyceridemia), and if triglycerides are persistently elevated or increasing, to further reduce triglycerides by the implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (Level of Evidence B- NR)<nowiki>''</nowiki>
|}
<ref name="pmid304233912" />
 
 
 


==References==
==References==
Line 288: Line 255:
[[fr:Hypertriglycéridémie]]
[[fr:Hypertriglycéridémie]]
[[pt:Hipertrigliceridemia]]
[[pt:Hipertrigliceridemia]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Lipopedia]]
[[Category:Endocrinology]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Genetic disorders]]
 
[[Category:Metabolic disorders]]
{{WH}}
[[Category:Overview complete]]
{{WS}}
[[Category:Template complete]]
[[Category:Lipid disorders]]
[[Category:Medical conditions related to obesity]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

Latest revision as of 23:58, 30 April 2023

Lipoprotein Disorders Main Page

Hyperlipoproteinemia Microchapters

Hypercholesterolemia Patient Information

Hypertriglyceridemia Patient Information

Overview

Classification

Familial hyperchylomicronemia
Familial hypercholesterolemia
Familial combined hyperlipidemia
Dysbetalipoproteinemia
Primary hypertriglyceridemia
Mixed hyperlipoproteinemia

Differential Diagnosis

Screening

ACC/AHA Guideline Recommendations

Summary

Treatment

Major recommendations for statin therapy

Therapeutic response to statin therapy

Blood cholesterol LDL and non-HDL treatment goals

Treatment in heart failure and hemodialysis

Primary prevention

Secondary prevention

Intensity of statin therapy in primary and secondary prevention

Safety Recommendations

Guideline on Lifestyle Management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, M.B.B.S. [2]; Ogheneochuko Ajari, MB.BS, MS [3]

Overview

Hypertriglyceridemia can occur due to various causes, including genetics, familial, metabolic and drugs.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Hypertriglyceridemia does not have life threatening causes.

Common Causes

Causes by Organ System

Cardiovascular Alström syndrome, apoprotein E deficiency, chylomicron levels raised (plasma), familial chylomicronemia, familial combined hyperlipidemia, familial hypertriglyceridemia, hyperlipoproteinemia, familial type 5, intermediate density lipoprotein levels raised (plasma or serum), metabolic syndrome, Reaven syndrome X
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic Systemic lupus erythematosus
Drug Side Effect Abiraterone, Amprenavir, atazanavir sulfate, atypical antipsychotics, bendrofluazide, beta-blockers, bexarotene, chlorthalidone, clomiphene, colesevelam hydrochloride, colestyramine, combined oral contraceptive pill, desvenlafaxine, diuretics, Drospirenone and Ethinyl estradiol, Efavirenz, estrogen replacement therapy, febuxostat, fosamprenavir, glucocorticoids, hydrochlorothiazide, interferon alpha, Interferon alfa-2b , Indinavir, Interferon gamma, linagliptin, lopinavir, Medroxyprogesterone, mirtazapine, non-nucleoside reverse transcriptase inhibitors, Norethindrone acetate and Ethinyl estradiol, Norgestimate and Ethinyl estradiol, Norgestrel and Ethinyl estradiol, olanzapine, oral isotretinoin, Pegaspargase, Pegylated interferon alfa-2b, propofol, protease inhibitors, raloxifene, ritonavir, Ruxolitinib,saquinavir, Siltuximab, tamoxifen, tazarotene, temsirolimus, tipranavir, tocilizumab, Tretinoin
Ear Nose Throat No underlying causes
Endocrine Cushing's syndrome, diabetes mellitus, hypothyroidism, insulin resistance, metabolic syndrome, polycystic ovary syndrome, Reaven syndrome X
Environmental No underlying causes
Gastroenterologic Acute pancreatitis, Alagille syndrome, carnitine palmitoyltransferase 1 deficiency, cholesteryl ester storage disease, glycogen storage disease type 1, glycogenosis type 1a, liver cirrhosis, non-alcoholic fatty liver disease
Genetic Alagille syndrome, Alström syndrome, apoprotein E deficiency, carnitine palmitoyltransferase 1 deficiency, cholesteryl ester storage disease, congenital generalized lipodystrophy type 1, deficiency of apolipoprotein C2 , familial chylomicronemia, familial combined hyperlipidemia, familial histiocytic reticulosis, familial hypertriglyceridemia, fish eye disease, glycogen storage disease type 1, glycogenosis type 1a, hyperlipoproteinemia, familial type 5, lecithin cholesterol acyltransferase deficiency, metabolic syndrome, Niemann-Pick disease type B, Reaven syndrome X, sphingomyelinase deficiency, Tangier disease
Hematologic Familial histiocytic reticulosis
Iatrogenic Parenteral nutrition
Infectious Disease No underlying causes
Musculoskeletal/Orthopedic Systemic lupus erythematosus
Neurologic Niemann-Pick disease type B, sphingomyelinase deficiency
Nutritional/Metabolic Alcohol, apoprotein E deficiency, chylomicron levels raised (plasma), deficiency of apolipoprotein C2, familial chylomicronemia, familial combined hyperlipidemia, familial hypertriglyceridemia, glycogen storage disease type 1, glycogenosis type 1a, high carbohydrate or high glycemic index, hyperlipoproteinemia, familial type 5, intermediate density lipoprotein levels raised (plasma or serum), lipodystrophy, lipoprotein lipase deficiency, metabolic syndrome, obesity, Reaven syndrome X, Tangier disease, very low density lipoprotein levels raised (plasma or serum), vitamin E deficiency, familial isolated
Obstetric/Gynecologic Polycystic ovary syndrome, pregnancy
Oncologic No underlying causes
Ophthalmologic Diabetes mellitus, Lecithin cholesterol acyltransferase deficiency
Overdose/Toxicity Alcohol
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte Chronic kidney disease, chronic renal insufficiency, diabetes mellitus, nephrotic syndrome, systemic lupus erythematosus
Rheumatology/Immunology/Allergy Macrophage activation syndrome, metabolic syndrome, paraproteinemias, Reaven syndrome X, systemic lupus erythematosus
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous Alcohol

Causes in Alphabetical Order

Diagnosis

2018 AHA ACC Guideline on the Management of Blood Cholesterol. Hypertriglyceridemia Recommendations

Class I
"1. In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting triglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors (obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or nephrotic syndrome, hypothyroidism), and medications that increase triglycerides(Level of Evidence: B-NR) "

[3]

Class IIa
" 2. In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or higher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to consider a persistently elevated triglyceride level as a factor favoring initiation or intensification of statin therapy (Level of Evidence B-R)".
'' 3. In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high triglyceride and to initiate statin therapy (Level of Evidence B-R)''
''4. In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and especially fasting triglycerides ≥1000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other causes of hypertriglyceridemia), and if triglycerides are persistently elevated or increasing, to further reduce triglycerides by the implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (Level of Evidence B- NR)''

[3]



References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP (2009). "Primary and secondary hypertriglyceridaemia". Curr Drug Targets. 10 (4): 336–43. PMID 19355858.
  2. ↑ Fallat RW, Glueck CJ (1976). "Familial and acquired type V hyperlipoproteinemia". Atherosclerosis. 23 (1): 41–62. PMID 1078394.
  3. ↑ 3.0 3.1 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS; et al. (2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". J Am Coll Cardiol. 73 (24): 3168–3209. doi:10.1016/j.jacc.2018.11.002. PMID 30423391.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=High_triglyceride_causes&oldid=1733849"